Both in Pharmaceuticals
Insmed vs Royalty Pharma
Over the past year INSM returned −18.4% and RPRX returned +65.2%; their daily moves had a correlation of 0.17.
INSM −18.4% RPRX +65.2%Growth of $1, one year, split-adjusted
| Metric | INSM | RPRX |
|---|---|---|
| Price | $115.63 | $58.22 |
| Market cap | $25.25B | $25.92B |
| Today | −1.73% | −0.26% |
| 1 month | −2.5% | −4.3% |
| 6 months | −24.6% | +25.6% |
| Year to date | −33.6% | +50.7% |
| 1 year | −15.6% | +66.2% |
| Revenue growth (YoY) | +296.1% | +16.5% |
| Gross margin | 84.2% | 100.0% |
| Net margin | −3.1% | 2.7% |
| P/E (TTM) | — | 31.8× |
| Price / sales | 22.2× | 10.2× |
| Net cash | $594.4M | -$8.23B |
| Dividend yield | — | 1.61% |
| Volatility (60d) | 68.9% | 24.0% |
| Short % of float | 5.0% | 2.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).